BIPOLAR DEPRESSION & SUICIDAL IDEATION
Severe Bipolar Depression with Recently Suicidal Patients post stabilization
NRX-100™ / NRX-101™
Phase 3FDA SPA, Breakthrough Therapy, Biomarker letter of Support – Integrating with P2b/3
Treatment of Suicidal Treatment-Resistant Bipolar Depression
Phase 3Currently Enrolling, Phase 2b/3 – Data Readout Expected Q4 2023
Expanded Access / Safety Study
Preclinical300+ Expected by Q2 2024
POST TRAUMATIC STRESS DISORDER (PTSD) WITH DEPRESSION & SUICIDALITY
PTSD in patients with Depression & Suicidality
Enrollment PendingEnrollment Pending – Data Readout Expected in 2023
CHRONIC PAIN WITH DEPRESSION
Depression in Patients with Chronic Pain
PlanningPlanning – Data Readout Expected in 2024
Expanded Access Policy on RTT: NRX-101 is not currently available outside of clinical trials.
Keep up with the latest news and updates about NRx through social media.